Cartesian Therapeutics closed at $6.77 on Nov 4, up 5.62%, 36.1% below its 52-week closing high. Volume of 35.2K shares was 0.28× its 20-day average (below normal).
Split-adjusted performance: +0.3% over one month, -18.8% over six months, -16.7% over one year.
Short interest was 1.9M shares at the Oct 15 settlement, up 1.0% from the prior report (15.6% of float, 11.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RNACCartesian Therapeutics | $6.77 | +5.62% | −18.8% | −100.0% | — | — | $204.8M | |
| UPBUpstream Bio | $3.75 | +10.62% | −59.2% | −17.5% | −5136.1% | — | $205.4M | Compare |
| NAGENiagen Bioscience | $2.57 | +8.90% | −48.3% | −4.3% | 3.2% | 12.7 | $203.4M | Compare |
| AKBAAkebia Therapeutics | $0.7252 | −0.08% | −51.0% | −21.4% | −18.1% | — | $201.0M | Compare |
| TRDAEntrada Therapeutics | $5.00 | +5.93% | −68.8% | −53.9% | −4762.0% | — | $194.7M | Compare |
| KROSKeros Therapeutics | $10.97 | +1.29% | −6.9% | −100.0% | — | — | $217.5M | Compare |
| ADCTADC Therapeutics SA | $1.71 | +10.00% | −55.8% | +2.2% | −86.1% | — | $217.7M | Compare |
| EVMNEvommune | $6.01 | +1.18% | −74.8% | — | — | — | $218.1M | Compare |
| ALXOALX Oncology Holdings | $1.38 | +6.98% | −34.0% | — | — | — | $190.8M | Compare |
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
